Triazines
These versatile molecules have a wide range of applications in fields like pharmaceuticals, agriculture, and materials science.
Explore the latest research on triazines using PubCompare.ai, an AI-driven platform that helps you locate the best protocols from literature, pre-prints, and patents, with seamless comparisons to enhance reproducibility and accuracy.
Streamline your research process and unlock new inshights with PubCompare.ai.
Most cited protocols related to «Triazines»
where a is an absorbance of sample solution with the present of FRAP solution and b is an absorbance of sample solution without the present of FRAP solution. All experiments were done in triplicate.
In subsets of experiments, mice were reconstituted with 5′-NT purified from Crotalus atrox venom (Sigma-Aldrich). Pilot dosing experiments revealed that 5′-NT could be used at concentrations as high as 500 U/kg i.p. without deleterious effects. After administration of 5′-NT, animals were subjected to normoxia or hypoxia, and examined for vascular leakage using Evan's blue as described before.
In other experiments, mice were administered the adenosine A2A receptor antagonist 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385; Tocris Cookson Inc.; dosage of 1 mg/kg i.p. plus 1 mg/kg s.c.), adenosine A2B receptor antagonist N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy]acetamide (MRS1754; a gift from K. Jacobson, Molecular Recognition Section, NIH, Bethesda, MD; dosage of 1 mg/kg i.p. plus 1 mg/kg s.c.) or the nonmetabolizable adenosine analogue NECA (Sigma-Aldrich; dosage of 0.1 mg/kg i.p. plus 0.1 mg/kg s.c. based on previous work [28 (link)]). After administration of drug, animals were subjected to normoxia or hypoxia, as indicated, and examined for vascular leakage using Evan's blue as described before. For assessment of pulmonary edema, lungs were collected, weighed, and dried by speed-vac. Weight differences before and after drying were used to calculate lung water content.
(i) Ferric Ion Reducing Antioxidant Power (FRAP Assay). FRAP activity was measured according to the method of Benzie and Strain [11 (link)]. Briefly, acetate buffer (300 mM, pH 3.6), TPTZ (2,4,6-tripyridyl-s-triazine) 10 mM in 40 mM HCl and FeCl3·6H2O (20 mM) were mixed in the ratio of 10 : 1 : 1 to obtain the working FRAP reagent. Test sample (0.5 mL) was mixed with 3 mL of working FRAP reagent and absorbance was measured at 593 nm after vortexing. Methanol solutions of FeSO4·7H2O ranging from 100 to 2000 μM were prepared and used for the preparation of the calibration curve of known Fe2+ concentration. The parameter equivalent concentration was defined as the concentration of antioxidant having a Ferric-TPTZ reducing ability equivalent to that of 1 mM FeSO4·7H2O.
Most recents protocols related to «Triazines»
Example 7
The title compound was prepared according to general procedure A using Intermediate 2 (15 mg, 0.04 mmol) and 2-amino-2-methyl-1-propanol (4.73 mg, 0.053 mmol). The crude product was purified by reverse-phase preparatory HPLC to give the title compound (2.8 mg, 16%) as a light yellow solid. 1H NMR (400 MHz, CD3OD) δ 1.40 (t, 3H), 1.47 (s, 6H), 3.70 (s, 2H), 4.16 (q, 2H), 7.20 (dd, 1H), 7.53 (dd, 1H), 7.71 (dd, 1H), 8.56-8.58 (m, 1H), 8.61 (d, 1H), 9.32 (s, 1H), 9.48 (d, 1H). MS (ES+) 411.0 (M+H).
Example 3
2,4-Dichloro-6-phenyl-1,3,5-triazine (30 g, 132.71 mmol), carbazole (17.75 g, 106.17 mmol), and sodium tert-butoxide (14.03 g, 145.98 mmol) were put in a round-bottomed flask and then, stirred with 650 ml of THF at ambient temperature for 12 hours. A solid generated therein was filtered and then, stirred in an aqueous layer for 30 minutes. After the filtration, the solid was dried to obtain 20 g (42%) of Intermediate Int-14.
Concentrations of thionine and cyanuric chloride used in the production of the TA-conjugated TC fabrics
TC-TA% (w.o.f.) | Amount of TA (mmol) | Amount of TCT (mmol) |
---|---|---|
0% (TC) | 0 | 0 |
0.72% (TC-TA1) | 0.125 | 0.5 |
1.44% (TC-TA2) | 0.25 | 1 |
5.76% (TC-TA3) | 1 | 4 |
11.52% (TC-TA4) | 2 | 8 |
5-triazine-2, 4, 6-triamine (melamine, 99%) from Merck, Darmstadt,
Germany, and polyoxymethylene (paraformaldehyde, extra pure) from
BDH, Poole, UK. Acetonitrile (ACN, p.a.), formic acid (FA, 98–100%),
phosphoryl trichloride (POCl3; 99%), α-hydro-ω-hydroxy-poly[oxy(1-methylethylene)]
[PPG4000; poly(propylene oxide), 4000 Da], iodoacetamide (IAA), 1,
4-dithiothreitol (DTT), triethylammonium bicarbonate (TEAB) buffer
(1 M), deuterium oxide (D2O, 99.9% atom-% D), and deuterated
acetonitrile (CD3CN, >99.8 atom-% D) were from Merck.
Trifluoroacetic
acid (TFA) was a product of VWR Chemicals (Radnor, PA, USA). The methanol
used in the Soxhlet extraction was of analytical grade from Prolabo,
obtained from VWR. Tetrahydrofuran (THF, 99.5% anhydrous, < 0.005%
H2O dried over molecular sieves, stabilized with 2, 6-di-tert-butyl-4-methylphenol) was from Scharlau (Barcelona,
Spain). Phenylphosphoric acid (PPA) was a product of TCI (Geel, Belgium).
The amphiphilic triblock copolymers Pluronic L61, L121, P123, and
F127, α, ω-hydroxy-poly(oxyethylene)-block-poly[oxy(1-methylethylene)]-block-poly(oxyethylene)
of varying overall molecular weights and block ratios were gifts from
BASF (Ludwigshafen, Germany). Dialysis tubing (MWCO 1000 Da) was from
Spectrum Laboratories (New Brunswick, NJ, USA). The GADDYYTAR peptides
(non- and mono-phosphorylated on tyrosine) were custom-synthesized
by LifeTein (Somerset, NJ, USA), and trypsin was from Promega (Madison,
WI, USA). All chemicals were used as received, unless otherwise noted.
Water used was prepared by Milli-Q or Ultra-Q equipment from Merck
Millipore (Bedford, MA, USA).